Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Akero Therapeutics, Inc
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and non-pregnant, non-lactating females between 18 - 75 years of age inclusive, based on the date of the screening visit.
Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes.
FibroScan measurement \> 8.5 kPa \[kilopascal\].
Biopsy-proven NASH. Must have had a liver biopsy obtained ≤ 180 days prior to randomization with fibrosis stage 2 to 3 and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:
* Steatosis (scored 0 to 3),
* Ballooning degeneration (scored 0 to 2), and
* Lobular inflammation (scored 0 to 3).
You may not be if
Weight loss \> 5% in the 3 months prior to screening until randomization or from the time of the diagnostic liver biopsy until randomization, whichever is longer.
Presence of cirrhosis on liver biopsy (stage 4 fibrosis).
